AK-1286

· Shanghai YingLi Pharmaceutical Co. Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for AK-1286, covering 2025-01-16 to 2025-01-16. Get the full timeline:

Most recent: Clinical Trial Update: A Study of AK-1286 in Patients With Advanced Solid Tumors [Phase 1]